Christopher Heery - 28 Sep 2022 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Role
Chief Medical Officer
Signature
/s/ Michelle Gilson, as Attorney-in-Fact
Issuer symbol
ACLX
Transactions as of
28 Sep 2022
Net transactions value
$0
Form type
4
Filing time
30 Sep 2022, 16:15:51 UTC
Previous filing
03 Feb 2022
Next filing
14 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACLX Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 28 Sep 2022 Common Stock 40,000 $19.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Start Date on the same day of the month as the Vesting Start Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Start Date" shall mean January 1, 2023.

Remarks:

Exhibit 24 - Power of Attorney